Literature DB >> 22150309

RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.

James K Mangan1, Nancy A Speck.   

Abstract

Translocations and mutations in the core binding factor genes, RUNX1 or CBFB, are found in acute myeloid and lymphocytic leukemia, therapy-related myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, and in familial platelet disorder with predisposition to acute myeloid leukemia. Here we review the biochemical and biological properties of the normal Runx1 protein, discuss the nature of RUNX1 mutations in myeloid leukemia, their prognostic significance, and the mutations that cooperate or co-exist with them in these various diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22150309      PMCID: PMC3248792          DOI: 10.1615/critrevoncog.v16.i1-2.80

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  107 in total

1.  The role of CBFbeta in AML1-ETO's activity.

Authors:  Colin Kwok; Bernd B Zeisig; Shuo Dong; Chi Wai Eric So
Journal:  Blood       Date:  2010-04-15       Impact factor: 22.113

2.  Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.

Authors:  F Dicker; C Haferlach; J Sundermann; N Wendland; T Weiss; W Kern; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

3.  Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Authors:  Alexander Kohlmann; Vera Grossmann; Hans-Ulrich Klein; Sonja Schindela; Tamara Weiss; Beray Kazak; Frank Dicker; Susanne Schnittger; Martin Dugas; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

4.  NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.

Authors:  B Hackanson; M Abdelkarim; J H Jansen; M Lübbert
Journal:  Leukemia       Date:  2010-01-21       Impact factor: 11.528

5.  Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity.

Authors:  Yizhou Liu; Wei Chen; Justin Gaudet; Matthew D Cheney; Liya Roudaia; Tomasz Cierpicki; Rachel C Klet; Kari Hartman; Thomas M Laue; Nancy A Speck; John H Bushweller
Journal:  Cancer Cell       Date:  2007-06       Impact factor: 31.743

6.  Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity.

Authors:  Christian Wichmann; Yvonne Becker; Linping Chen-Wichmann; Vitali Vogel; Anna Vojtkova; Julia Herglotz; Sandra Moore; Joachim Koch; Jörn Lausen; Werner Mäntele; Holger Gohlke; Manuel Grez
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

7.  C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.

Authors:  Yue-Ying Wang; Li-Juan Zhao; Chuan-Feng Wu; Ping Liu; Lin Shi; Yang Liang; Shu-Min Xiong; Jian-Qing Mi; Zhu Chen; Ruibao Ren; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

8.  Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.

Authors:  Takeshi Corpora; Liya Roudaia; Zaw Min Oo; Wei Chen; Ekaterina Manuylova; Xiongwei Cai; Michael J Chen; Tomasz Cierpicki; Nancy A Speck; John H Bushweller
Journal:  J Mol Biol       Date:  2010-08-11       Impact factor: 5.469

9.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

10.  Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation.

Authors:  Christopher R Dowdy; Ronglin Xie; Dana Frederick; Sadiq Hussain; Sayyed K Zaidi; Diana Vradii; Amjad Javed; Xiangen Li; Stephen N Jones; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  Hum Mol Genet       Date:  2009-12-24       Impact factor: 6.150

View more
  52 in total

1.  In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.

Authors:  Jason H Mendler; Kati Maharry; Heiko Becker; Ann-Kathrin Eisfeld; Leigha Senter; Krzysztof Mrózek; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Michael A Caligiuri; Rebecca B Klisovic; Joseph O Moore; Thomas H Carter; Guido Marcucci; Clara D Bloomfield
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

2.  CBFβ and RUNX1 are required at 2 different steps during the development of hematopoietic stem cells in zebrafish.

Authors:  Erica Bresciani; Blake Carrington; Stephen Wincovitch; MaryPat Jones; Aniket V Gore; Brant M Weinstein; Raman Sood; P Paul Liu
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 3.  Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Authors:  Bin E Li; Patricia Ernst
Journal:  Exp Hematol       Date:  2014-09-28       Impact factor: 3.084

4.  Distinct temporal requirements for Runx1 in hematopoietic progenitors and stem cells.

Authors:  Joanna Tober; Amanda D Yzaguirre; Eileen Piwarzyk; Nancy A Speck
Journal:  Development       Date:  2013-08-07       Impact factor: 6.868

5.  Tyrosyl phosphorylation toggles a Runx1 switch.

Authors:  Benjamin G Neel; Nancy A Speck
Journal:  Genes Dev       Date:  2012-07-15       Impact factor: 11.361

6.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

7.  Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.

Authors:  Yue Zhang; Xiaomei Yan; Goro Sashida; Xinghui Zhao; Yalan Rao; Susumu Goyama; Susan P Whitman; Nicholas Zorko; Kelsie Bernot; Rajeana M Conway; David Witte; Qian-Fei Wang; Daniel G Tenen; Zhijian Xiao; Guido Marcucci; James C Mulloy; H Leighton Grimes; Michael A Caligiuri; Gang Huang
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

8.  Defining a tissue stem cell-driven Runx1/Stat3 signalling axis in epithelial cancer.

Authors:  Cornelia Johanna Franziska Scheitz; Tae Seung Lee; David James McDermitt; Tudorita Tumbar
Journal:  EMBO J       Date:  2012-10-02       Impact factor: 11.598

Review 9.  New insights into the role of Runx1 in epithelial stem cell biology and pathology.

Authors:  Cornelia Johanna Franziska Scheitz; Tudorita Tumbar
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

10.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Authors:  V I Gaidzik; V Teleanu; E Papaemmanuil; D Weber; P Paschka; J Hahn; T Wallrabenstein; B Kolbinger; C H Köhne; H A Horst; P Brossart; G Held; A Kündgen; M Ringhoffer; K Götze; M Rummel; M Gerstung; P Campbell; J M Kraus; H A Kestler; F Thol; M Heuser; B Schlegelberger; A Ganser; L Bullinger; R F Schlenk; K Döhner; H Döhner
Journal:  Leukemia       Date:  2016-05-03       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.